Cardiology
RSSArticles
-
Full January 2006 Issue in PDF
-
Clinical Briefs in Primary Care supplement
-
Pharmacology Watch: FDA Recommends Approval of Muraglitazar, But May Need To Reconsider
Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions -
Special Feature: Rapid Response Teams: Are the Benefits Worth the Costs?
The Institute for Healthcare Improvement (IHI) is a not-for-profit organization dedicated to the improvement of health by advancing the quality of health care. -
PAC-Man: Is the Game Over in the ICU?
Critically ill patients with the acute respiratory distress syndrome (ARDS) and/or multi-organ failure pose a challenge in maintaining effective circulatory function while avoiding volume overload. -
Risk of Catheter-Related Blood Stream Infections with PICC Lines in Hospitalized Patients
Peripherally Inserted Central Venous Catheters (PICCs) are now routinely used in ICUs for long-term central venous access. -
Supplemental Perioperative Oxygen and the Risk of Surgical Wound Infection
The objective of this study was to test the hypothesis that supplemental oxygen reduces infection risk in patients following colorectal surgery. -
Pharmacology Watch
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions -
Pharmacology Update: Mecasermin Injection (Increlex)
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex. -
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.